Marker Therapeutics, Inc.

Marker Therapeutics is a clinical-stage immuno-oncology company dedicated to developing and commercializing next-generation T cell-based immunotherapies for patients with a wide range of blood cancers and solid tumors. Their innovative Multi-Antigen Recognizing (MAR) T cell therapy uses non-genetically engineered T cells to recognize and kill tumor cells effectively, offering a potentially safer and more durable treatment option compared to existing therapies. This approach has been tested across seven clinical indications, demonstrating a promising safety profile and durable anti-tumor responses in both hematologic malignancies and solid tumors.

Marker Therapeutics is headquartered in Houston, Texas and their lead product candidate, MT-601, is currently being evaluated in a Phase 1 study for patients with lymphoma who have relapsed or are ineligible for anti-CD19 CAR-T cell therapy. The company is actively seeking non-dilutive funding to support the development of their pipeline, including their investigational MT-401-OTS product, which is designed to be an off-the-shelf treatment for Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS).

Marker Therapeutics is a clinical-stage immuno-oncology company dedicated to developing and commercializing next-generation T cell-based immunotherapies for patients with blood cancers and solid tumors. Their innovative Multi-Antigen Recognizing T cell (MAR-T cell) technology utilizes non-genetically engineered T cells to recognize and kill multiple tumor targets, offering a potentially safer and more effective treatment option compared to current engineered T cell approaches. Marker's goal is to improve patient outcomes by bringing novel T cell therapies to the market, while prioritizing the preservation of financial resources and focusing on operational excellence.

Marker Therapeutics fosters a collaborative and innovative culture, driven by a shared passion for developing cutting-edge cancer immunotherapies. Their team, located in Houston, Texas, is comprised of talented and motivated professionals who are committed to improving cancer treatments and enhancing the lives of patients. This shared goal creates a dynamic and supportive environment where employees have the opportunity to work on cutting-edge cell therapies, pushing the boundaries of scientific research and making a real difference in the field of oncology.

Marker Therapeutics, Inc. is committed to fostering a diverse, equitable, and inclusive workplace where all employees feel valued, respected, and empowered. The company recognizes the importance of attracting and retaining a diverse workforce, reflecting the patients they serve and the communities in which they operate. This commitment is demonstrated through their efforts to create an environment where individuals from all backgrounds feel welcome, respected, and supported, allowing them to contribute their unique talents and perspectives.